The GeoTeam has been monitoring developments that might impact REPRO MED SYS INC (OOTC:REPR) and its flagship product, the FREEDOM60 pump (mechanical infusion pump system) and related needle sets used to deliver medication to primary immune deficiency patients.

We noted that the FDA recently approved Baxter’s HQVIA (Immune Globulin Infusion 10% (Human) with Recombinant
Human Hyaluronidase) for subcutaneous treatment for adult patients with primary immunodeficiency (PI).  This introduces a new drug to the market for subcutaneous treatment of PI with several advantages over the most wide used drug for this condition, CSL Behring’s Hizentra.

Hizentra treats patients who use and have used REPR’s pump system. HQVIA only has to be administered every 3-4 weeks with one injection site, versus Hizentra which has to be injected every two weeks.  If HQVIA gains significant market share, fewer injections would reduce the use of REPR’s needle sets, impacting future revenues, since REPS sell needle sets that are used with its pump system. Part of REPR’s ongoing business is the continued sale of its products made specifically for its pumps.

Additionally, some investors have speculated that if Freedom users and potential PI candidates choose to switch to HQVIA, sales of the Freedom60 Pump could suffer since the Freedom mechanism is not currently approved by the FDA to  administer HQVIA.

Optimistic View on the Freedom60 Pump with use of HQVIA

GeoInvesting has taken a more optimistic view on the Freedom60 pump.  

To learn why we continue to maintain our optimistic view REPR, please go here.

Notes:

  • We coded REPR as a GeoBargain on October 6, 2014 and published a related article on October 7, 2014.
  • We continue to hold our position in REPR and will consider adding stock as circumstances justify.

To stay ahead of the market with GeoInvesting arbitrage and learn about investment ideas not yet digested by the market, Sign up now for More Research and Insight